SOURCE: Dynavax Technologies

Dynavax Technologies

November 30, 2016 07:00 ET

Dynavax to Present Clinical Data from Immuno-oncology Product Candidate, SD-101

Data to be Presented at ASH Annual Meeting on Sunday, December 4th, in San Diego

BERKELEY, CA--(Marketwired - November 30, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present clinical data from a Phase 1/2 clinical trial evaluating its immuno-oncology product, SD-101, in patients with low-grade, B cell lymphoma. The poster presentation will be made at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition.

  • Abstract Name: SD-101, a Novel Class C CpG-Oligodeoxynucleotide Toll-like Receptor 9 Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial
  • Abstract Number: 2974
  • Date and Time: Sunday, December 4, 2016 from 6:00 p.m. EST to 8:00 p.m. EST
  • Session Name: 623. Mantle Cell, Follicular and Other Indolent B-Cell Lymphoma - Clinical Studies: Poster II
  • Location: San Diego Convention Center, Hall GH
  • Note: Abstract will also be published online on December 1, 2016, in the supplemental volume of the journal Blood

About SD-101

SD-101 is Dynavax's proprietary, second-generation, Toll-like Receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide. SD-101 activates multiple anti-tumor activities of innate immune cells and activates plasmacytoid dendritic cells to stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as SD-101 enhance T and B cell responses and provide potent Type 1 interferon induction and maturation of plasmacytoid dendritic cells to antigen-presenting cells. SD-101 is being evaluated in several Phase 1/2 oncology studies to assess its safety and activity.

For information about SD-101 trials that are currently recruiting patients, please visit

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine, and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit

Contact Information

  • Contact:
    Michael Ostrach
    Chief Financial Officer
    Email contact